636 related articles for article (PubMed ID: 15341559)
21. Raloxifene: results from the MORE study.
Agnusdei D; Iori N
J Musculoskelet Neuronal Interact; 2000 Dec; 1(2):127-32. PubMed ID: 15758505
[TBL] [Abstract][Full Text] [Related]
22. [SERM & bone metabolism: protective effects of SERM against fracture risk and its long-term beneficial effects].
Inaba M
Clin Calcium; 2004 Oct; 14(10):27-31. PubMed ID: 15577128
[TBL] [Abstract][Full Text] [Related]
23. Osteodensitometry in healthy postmenopausal women.
Prescrire Int; 2008 Apr; 17(94):68-72. PubMed ID: 18536138
[TBL] [Abstract][Full Text] [Related]
24. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women.
Barrett-Connor E; Mosca L; Collins P; Geiger MJ; Grady D; Kornitzer M; McNabb MA; Wenger NK;
N Engl J Med; 2006 Jul; 355(2):125-37. PubMed ID: 16837676
[TBL] [Abstract][Full Text] [Related]
25. Treatment of established postmenopausal osteoporosis with raloxifene: a randomized trial.
Lufkin EG; Whitaker MD; Nickelsen T; Argueta R; Caplan RH; Knickerbocker RK; Riggs BL
J Bone Miner Res; 1998 Nov; 13(11):1747-54. PubMed ID: 9797484
[TBL] [Abstract][Full Text] [Related]
26. Teriparatide: new preparation. Osteoporosis: less well evaluated than alendronic acid.
Prescrire Int; 2005 Feb; 14(75):5-9. PubMed ID: 15747448
[TBL] [Abstract][Full Text] [Related]
27. Pharmacologic prevention of osteoporotic fractures.
Zizic TM
Am Fam Physician; 2004 Oct; 70(7):1293-300. PubMed ID: 15508540
[TBL] [Abstract][Full Text] [Related]
28. Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective.
Boonen S; Marin F; Mellstrom D; Xie L; Desaiah D; Krege JH; Rosen CJ
J Am Geriatr Soc; 2006 May; 54(5):782-9. PubMed ID: 16696744
[TBL] [Abstract][Full Text] [Related]
29. Risk factors for breast cancer in older women: the relative contribution of bone mineral density and other established risk factors.
Cauley JA; Song J; Dowsett SA; Mershon JL; Cummings SR
Breast Cancer Res Treat; 2007 Apr; 102(2):181-8. PubMed ID: 17028986
[TBL] [Abstract][Full Text] [Related]
30. Disability after clinical fracture in postmenopausal women with low bone density: the fracture intervention trial (FIT).
Fink HA; Ensrud KE; Nelson DB; Kerani RP; Schreiner PJ; Zhao Y; Cummings SR; Nevitt MC
Osteoporos Int; 2003 Jan; 14(1):69-76. PubMed ID: 12577187
[TBL] [Abstract][Full Text] [Related]
31. Strontium ranelate: vertebral and non-vertebral fracture risk reduction.
Seeman E
Curr Opin Rheumatol; 2006 Jun; 18 Suppl 1():S17-20. PubMed ID: 16735841
[TBL] [Abstract][Full Text] [Related]
32. Osteoporosis a disease for all; in Lebanon.
Ghassan M; Alexandre N; Joseph W; Fadi H; Georges F; Joseph H; Marie Hélène GY
Clin Calcium; 2004 Sep; 14(9):116-22. PubMed ID: 15577123
[TBL] [Abstract][Full Text] [Related]
33. [Raloxifene (Evista) in the treatment of postmenopausal osteoporosis--the profile of the patient].
Kastelan D; Korsić M
Reumatizam; 2005; 52(2):67-70. PubMed ID: 16689133
[TBL] [Abstract][Full Text] [Related]
34. Treatment with denosumab reduces the incidence of new vertebral and hip fractures in postmenopausal women at high risk.
Boonen S; Adachi JD; Man Z; Cummings SR; Lippuner K; Törring O; Gallagher JC; Farrerons J; Wang A; Franchimont N; San Martin J; Grauer A; McClung M
J Clin Endocrinol Metab; 2011 Jun; 96(6):1727-36. PubMed ID: 21411557
[TBL] [Abstract][Full Text] [Related]
35. Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX.
Kanis JA; Johansson H; Oden A; McCloskey EV
Bone; 2009 Jun; 44(6):1049-54. PubMed ID: 19254788
[TBL] [Abstract][Full Text] [Related]
36. Raloxifene. Not better than estrogen.
Can Fam Physician; 2000 Aug; 46():1592-6, 1599-603. PubMed ID: 10955178
[TBL] [Abstract][Full Text] [Related]
37. [MORE study(raloxifene)].
Itabashi A
Nihon Rinsho; 2004 Feb; 62 Suppl 2():442-9. PubMed ID: 15035168
[No Abstract] [Full Text] [Related]
38. Effects of long-term strontium ranelate treatment on the risk of nonvertebral and vertebral fractures in postmenopausal osteoporosis: Results of a five-year, randomized, placebo-controlled trial.
Reginster JY; Felsenberg D; Boonen S; Diez-Perez A; Rizzoli R; Brandi ML; Spector TD; Brixen K; Goemaere S; Cormier C; Balogh A; Delmas PD; Meunier PJ
Arthritis Rheum; 2008 Jun; 58(6):1687-95. PubMed ID: 18512789
[TBL] [Abstract][Full Text] [Related]
39. Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis.
Lindsay R; Scheele WH; Neer R; Pohl G; Adami S; Mautalen C; Reginster JY; Stepan JJ; Myers SL; Mitlak BH
Arch Intern Med; 2004 Oct; 164(18):2024-30. PubMed ID: 15477438
[TBL] [Abstract][Full Text] [Related]
40. Vascular events in the Multiple Outcomes of Raloxifene Evaluation (MORE) trial: incidence, patient characteristics, and effect of raloxifene.
Duvernoy CS; Kulkarni PM; Dowsett SA; Keech CA
Menopause; 2005; 12(4):444-52. PubMed ID: 16037760
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]